MammaPrint, the 70-gene assay, helps optimize treatment strategy, including reclassifying 46% of clinically high risk patients as MammaPrint low risk, enabling them to safely forego chemotherapy. BluePrint, the complementary 80-gene assay, identifies unique molecular subtypes and determines patients who may benefit from neoadjuvant chemotherapy with an increased likelihood of pathologic complete response (pCR) to inform surgery decisions.
